Comparative Evaluation of Intraperitoneal Ropivacaine and Placebo for Postoperative Analgesia in Laparoscopic Cholecystectomy: A Randomized Double-Blind Study
Abstract
Background: Laparoscopic cholecystectomy is associated with significant postoperative pain despite its minimally invasive nature. Intraperitoneal ropivacaine has been proposed as an effective multimodal analgesic technique to reduce postoperative pain, opioid consumption, and facilitate early recovery. Materials and Methods: A prospective randomized double-blind study was conducted on 60 ASA I-II patients undergoing elective laparoscopic cholecystectomy. Patients received either intraperitoneal ropivacaine (3 mg/kg diluted to 100 mL) or 100 mL normal saline. Postoperative VAS scores, time to first rescue analgesia, total analgesic consumption, and adverse effects were compared over 24 hours. Results: Patients receiving ropivacaine had significantly lower postoperative VAS scores at all time points (p<0.01), prolonged time to first rescue analgesia (228.5 ÷ 43.7 vs. 126.2 ÷ 35.4 min, p<0.001), and reduced 24- hour analgesic consumption (850 ≤ 120 vs. 1350 ≤ 150 mg, p<0.001). Adverse effects were minimal and comparable between the groups. Conclusion: Intraperitoneal ropivacaine provides safe and effective postoperative analgesia following laparoscopic cholecystectomy by reducing pain scores, delaying rescue analgesia, and decreasing analgesic requirements. It is a valuable component of multimodal analgesia and enhances postoperative recovery.